{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:47:13Z","timestamp":1777607233065,"version":"3.51.4"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1097\/meg.0b013e32832a8c4c","type":"journal-article","created":{"date-parts":[[2010,2,4]],"date-time":"2010-02-04T07:55:23Z","timestamp":1265270123000},"page":"270-277","source":"Crossref","is-referenced-by-count":102,"title":["Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support"],"prefix":"10.1097","volume":"22","author":[{"given":"Jason","family":"Grebely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista A.","family":"Genoway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Viljoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Khara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doug","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Storms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse D.","family":"Raffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"DeVlaming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210207","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"R2-3-20210207","first-page":"889","article-title":"Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection","volume":"165","author":"Patrick","year":"2001","journal-title":"CMAJ"},{"key":"R3-3-20210207","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2105\/AJPH.91.1.23","article-title":"Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City","volume":"91","author":"Diaz","year":"2001","journal-title":"Am J Public Health"},{"issue":"Suppl 1","key":"R4-3-20210207","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"R6-3-20210207","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","article-title":"Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic","volume":"20","author":"Mehta","year":"2006","journal-title":"AIDS (London, England)"},{"key":"R7-3-20210207","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"J Community Health"},{"issue":"Suppl 1","key":"R9-3-20210207","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1002\/hep.1840360727","article-title":"Prevention and treatment of hepatitis C in injection drug users","volume":"36","author":"Edlin","year":"2002","journal-title":"Hepatology"},{"key":"R10-3-20210207","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1071\/AH080570","article-title":"Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings","volume":"32","author":"Treloar","year":"2008","journal-title":"Aust Health Rev"},{"key":"R11-3-20210207","first-page":"900","article-title":"Interferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation","volume":"42","author":"Van Thiel","year":"1995","journal-title":"Hepatogastroenterology"},{"key":"R12-3-20210207","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users","volume":"34","author":"Backmund","year":"2001","journal-title":"Hepatology"},{"issue":"5","key":"R13-3-20210207","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1086\/427449","article-title":"Follow-up studies of treatment for hepatitis C virus infection among injection drug users","volume":"40","author":"Dalgard","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R14-3-20210207","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(02)00010-8","article-title":"Treating hepatitis C in methadone maintenance patients: an interim analysis","volume":"67","author":"Sylvestre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"R15-3-20210207","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0149-2918(02)80065-0","article-title":"Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b","volume":"24","author":"Neri","year":"2002","journal-title":"Clin Ther"},{"key":"R16-3-20210207","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"R17-3-20210207","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/S0002-9270(03)00708-1","article-title":"Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse","volume":"98","author":"Van Thiel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R18-3-20210207","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance","volume":"40","author":"Mauss","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"R19-3-20210207","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1086\/427448","article-title":"Treatment for hepatitis C virus infection among current injection drug users in Australia","volume":"40","author":"Matthews","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R20-3-20210207","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2005.06.002","article-title":"The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone","volume":"29","author":"Sylvestre","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"R21-3-20210207","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00042737-200602000-00008","article-title":"Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes","volume":"18","author":"Robaeys","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R22-3-20210207","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hep.21470","article-title":"Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants","volume":"45","author":"Jeffrey","year":"2007","journal-title":"Hepatology"},{"key":"R23-3-20210207","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1360-0443.2006.01698.x","article-title":"Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification program","volume":"102","author":"Guadagnino","year":"2007","journal-title":"Addiction (Abingdon, England)"},{"key":"R24-3-20210207","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/j.1440-1746.2007.05032.x","article-title":"Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users","volume":"22","author":"Grebely","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R25-3-20210207","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.drugpo.2007.01.009","article-title":"Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection","volume":"18","author":"Grebely","year":"2007","journal-title":"The International journal on drug policy"},{"key":"R26-3-20210207","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.21791","article-title":"Hepatitis C treatment in difficult-to-treat psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects","volume":"46","author":"Schaefer","year":"2007","journal-title":"Hepatology"},{"key":"R27-3-20210207","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1086\/425361","article-title":"Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users","volume":"39","author":"Backmund","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R28-3-20210207","first-page":"370A","article-title":"Infrequent hepatitis C virus (HCV) re-infection after sustained virological response (SVR) among current and former injection drug users (IDUs) having received treatment for HCV infection [Abstract 296]","volume":"46","author":"Grebely","year":"2007","journal-title":"Hepatology"},{"key":"R29-3-20210207","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.drugpo.2007.01.010","article-title":"Integrating HCV services for drug users: a model to improve engagement and outcomes","volume":"18","author":"Sylvestre","year":"2007","journal-title":"The Int J Drug Policy"},{"key":"R30-3-20210207","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.qai.0000131932.21612.49","article-title":"Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection","volume":"37","author":"Fishbein","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R31-3-20210207","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2893.2005.00548.x","article-title":"The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre","volume":"12","author":"Restrepo","year":"2005","journal-title":"J Viral Hepat"},{"key":"R32-3-20210207","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1086\/344907","article-title":"Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment","volume":"36","author":"Fleming","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R33-3-20210207","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7326\/0003-4819-136-4-200202190-00008","article-title":"Surprisingly small effect of antiviral treatment in patients with hepatitis C","volume":"136","author":"Falck-Ytter","year":"2002","journal-title":"Ann Intern Med"},{"issue":"5","key":"R34-3-20210207","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1086\/427445","article-title":"Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users","volume":"40","author":"Strathdee","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R35-3-20210207","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2007.09.008","article-title":"Barriers associated with the treatment of hepatitis C virus infection among illicit drug users","volume":"93","author":"Grebely","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"R36-3-20210207","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1086\/427446","article-title":"Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia","volume":"40","author":"Doab","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R37-3-20210207","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0755-4982(05)84158-2","article-title":"Willing to undergo hepatitis C treatment in a sample of injection drug users in Toronto, Canada","volume":"34","author":"Fischer","year":"2005","journal-title":"Presse Med"},{"key":"R38-3-20210207","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New Engl J Med"},{"key":"R39-3-20210207","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R40-3-20210207","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000104884","article-title":"Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study","volume":"13","author":"Krook","year":"2007","journal-title":"Eur Addict Res"}],"container-title":["European Journal of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042737-201003000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T09:51:24Z","timestamp":1739785884000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042737-201003000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0b013e32832a8c4c","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}